Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
IBD
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - IBD
    TopAbstracts in IBD 11/11/2008 - (DGNews)
    TopAbstracts in IBD 10/28/2008 - (DGNews)
    Flexible Dosing of Infliximab Ensures Long-Term Response in Crohn's Disease: Presented at UEGW - (DGDispatch)
    No Benefit to Methotrexate Induction and Maintenance Therapy in Crohn's Disease: Presented at UEGW - (DGDispatch)
    Modified-Release Mesalazine Effective, Safe, and Useful for Patients With Refractory Ulcerative Colitis: Presented at UEGW - (DGDispatch)

    News archive

     Recent webcasts/CME - IBD
    • State of the Science in IBS-C and Other Constipation-Related Disorders: Where Are We Now, and Where Are We Going?
    • Managing IBS-C and Other Constipation-Related Disorders: Where Are We Now?
    • Managing IBS-C and Other Constipation-Related Disorders: Where Are We Going?
    • Inflammatory Bowel Diseases and Biologic Agents
      Therapeutic Options for Inflammatory Bowel Disease

      Webcasts/CME archive

       Recent cases - IBD
        An Elderly Woman with 'Red Man Syndrome' in Association with Oral Vancomycin Therapy: A Case Report
        Sweet's Syndrome in a Patient with Crohn's Disease: A Case Report
        Stroke in Inflammatory Bowel Disease: A Report of Two Cases and Review of the Literature
        Colonic Perforation Following Mild Abdominal Trauma in a Patient with Crohn's Disease: A Case Report
        Takayasu's Arteritis Associated wWith Crohn's Disease: A Case Report

        Cases archive
          




        my personal edition > ibd > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Mesalamine 1-g Once-Daily Suppository as Effective as 0.5 g Three Times Daily for Ulcerative Proctitis: Presented at DDW

          By Ed Susman

          SAN DIEGO -- May 22, 2008 -- Treatment of mild to moderate active ulcerative proctitis can be simplified without increasing adverse effects or diminishing efficacy, researchers reported here at Digestive Diseases Week 2008 (DDW).

          Both the mesalamine 1-g suppository once daily and the mesalamine 0.5-g suppository 3 times daily were very well accepted, "but patients preferred to take suppositories once daily," said investigator Tilo Andus, MD, Chief of Internal Medicine, Krankenhaus Bad Cannstatt, Stuttgart, Germany.

          Dr. Andus and collaborators in Germany, Russia, Ukraine, and Israel recruited 408 patients for the trial; 403 patients were in the intention-to-treat cohort and 354 patients were evaluated as per-protocol patients.

          Remission was defined as a score of <4 on the Disease Activity Index (DAI).

          Average age was 42 years; 55% of patients were women. Mean duration of disease was 2.2 years for the 201 patients in the once-daily treatment group and 3.6 years in the 3-times-daily group, but some patients had the disease for as long as 36 and 31 years, respectively.

          No differences in rates of remission were observed between the intention-to-treat population and the per-protocol population, and between the once-daily group and the 3-times-daily group.

          "Rectal mesalamine treatment induced a prompt cessation of clinical symptoms," Dr. Andus said in his poster presentation on May 20. He found no significant differences in efficacy, safety, or tolerability between the 2 treatment arms.

          In the primary outcome measure, remission rates were 87.9% and 90.7% with once-daily and 3-times-daily treatment in the per-protocol population, which reached statistical significance (P = .00027 for equivalence).

          In the intention-to-treat population, 84% and 84.7% of patients achieved remission in the once-daily and 3-times-daily groups, which also reached statistical significance (P = .00008).

          Outcomes were similar between the treatment groups in the secondary measures of clinical remission, endoscopic remission, mucosal healing, histological improvement, therapeutic success, and therapeutic benefit.

          Funding for this study was provided by Dr. Falk Pharma.


          [Presentation title: A Novel High Dose 1 g Mesalamine Suppository (Salofalk) Is as Efficacious as 500 Mg TID Suppositories in Mild to Moderate Active Ulcerative Proctitis: A Multicenter, Randomized Trial. Abstract T1137]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send